Recent Press Releases

Utah-based PhotoPharmics Selected as Global Top 50 Startup

PhotoPharmics today announced it has been selected by MedTech Innovator as a top 50 medtech startup and will be showcased in MedTech’s 2021 cohort featuring the industry’s most transformative device, diagnostic, and digital health technologies.

“We’re delighted with this designation and honor,” said Kent Savage, CEO of PhotoPharmics. “International attention from leading organizations like MedTech brings us closer to delivering on our mission of innovation, particularly providing a breakthrough, non-invasive treatment for people suffering from the symptoms of Parkinson’s disease.”

“We’re seeing a real breakthrough here,” said Savage. “Once approved, this may be the first therapy to address non-motor problems in Parkinson’s, one that we feel promises a nearly 5-year reversal of symptom progression—based on the results of our last clinical trial.”

read more

PhotoPharmics Innovations Address Global Health Inequalities

Innovation not only brings improved treatments to address large, unmet medical needs but can also improve access for underserved patient populations. PhotoPharmics today announced its intent to leverage its Breakthrough Device designation, CMS’s MCIT rule, and global delivery channels to deliver its treatments for Parkinson’s and neurodegenerative diseases to individuals regardless of their location or income.

The strength of the Company’s phase 2 data encouraged FDA to grant Breakthrough Device designation (details here) for its home-based, non-invasive therapeutic device in Parkinson’s. This designation speeds FDA’s review process for devices that provide for more effective treatment for life-threatening or irreversibly debilitating diseases.

read more

Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s

July 14, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced a collaboration with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center to conduct an at home, telemedicine, phase 3 trial to establish safety and efficacy for the company’s non-invasive specialized phototherapy device for Parkinson’s disease.

read more

FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease

April 29, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy, today announced that it has received FDA Breakthrough device designation for the company’s non-invasive Specialized Phototherapy Device.  This prescription device is intended as an adjunct therapy for the treatment of Parkinson’s disease. It is intended to be used concurrently with standard dopaminergic therapy and is designed primarily for home use.

“Very few device companies receive Breakthrough designation. Our device is the first specialized phototherapy device to achieve this status,” said Kent Savage, CEO of PhotoPharmics. “Our focus is to help people with Parkinson’s improve function and return to what they enjoy doing most. We think this recognition by FDA validates our work.”

read more

Largest Phototherapy Trial for Parkinson’s Disease

February 10, 2020, Salt Lake City, UT— PhotoPharmics announced today plans to conduct a pivotal trial to assess the efficacy of Celeste®, the company’s specialized phototherapy device to improve overall function in Parkinson’s disease (PD). The Celeste device builds on the company’s innovative Spectramax™ technology that has been used in previous human research. The company anticipates enrolling approximately 200 people in what will likely be the largest trial of its kind, the final details of which are forthcoming.

read more

Pivotal Parkinson’s Disease Clinical Trial Results Released at the International Movement Disorders Society Congress

October 5, 2018, Hong Kong, China—PhotoPharmics today released the results of its multinational, double blind, randomized controlled trial in Parkinson’s disease at the annual International Movement Disorders Society meeting in Hong Kong. The study is entitled “Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic therapy.”

read more

Media Contact

Brett Walker